Three areas in Section 202 of the Bayh-Dole Act that require action to ensure sufficient rights in patents on coronavirus relevant inventions

For more on KEI’s work on COVID-19, see keonline.org/coronavirus. As the US and other governments begin to expend large amounts of money on research and development related to the control, prevention and treatment of the coronavirus pandemic, there are important… Continue Reading

DHHS Listening Session on WHA 2018: Comment on Agenda Item 11.7 Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-Communicable Diseases, to be held in 2018

On Friday May 11, 2018, the Department of Health and Human Services (DHHS) held its annual listening session in advance of the upcoming Seventy-First World Health Assembly. Comments were limited to 2 minutes, with no time set aside for a… Continue Reading

DHHS Listening Session on WHA 2018: Comment on Agenda Item 11.6 Global strategy and plan of action on public health, innovation, and intellectual property

On Friday May 11, 2018, the Department of Health and Human Services (DHHS) held its annual listening session in advance of the upcoming Seventy-First World Health Assembly. Comments were limited to 2 minutes, with no time set aside for a… Continue Reading

KEI Comments to DHHS on WHA68 agenda 11.2, Framework of Engagement with Non-State Actors

On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_1-en.pdf
jimmy-claire_1024x.png

Continue Reading

2009: PAHO dispute over standards for transparency of economic data for pharmaceutical industry

Today the executive board of the Pan American Health Organization (PAHO) is considering a proposal to have more transparency of the economics of the pharmaceutical industry. (I have separately blogged about this on the Huffpo). Specifically, an amendment offered to a PAHO EB resolution on research, proposed the following:

Continue Reading